The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Funding Opportunities

DoD announces FY20 anticipated funding opportunities

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The FY20 Defense Appropriations Act provides funding to the Department of Defense Pancreatic Cancer Research Program to support pancreatic cancer research.

The funding is directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs at the U.S. Army Medical Research and Development Command.

The PCARP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity. This pre-announcement should not be construed as an obligation by the government. The FY20 PCARP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released.

For more information, visit http://cdmrp.army.mil/.

Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019). 
By Sara Willa Ernst and Paul Goldberg
Trials & Tribulations

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account